Adaptin Bio, Inc.
APTN
The Company's objective is to develop and commercialize products utilizing novel technology that enhances the delivery of drugs and other compounds to the brain and other tissues for a variety of indications. Our novel technology was originally developed by researchers in the Department of Neurosurgery at Duke University and licensed by us in 2023.
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$5M
▼ -65.5% YoY
Op. Margin
–
ROIC
-3111.13%
▼ -2002.4pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$3M
▼ -635.9% YoY
Net Debt
-$430K
Net Cash Position
Cash & Equiv.
$430K
Continue Research
SourceComputed from the 10-Q filed 12 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 14 Nov 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with APTN
Spot a number that looks wrong? Check it in APTN's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing APTN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.